SIMCERE PHARMAC. GRP LTD (F:S2P) — Market Cap & Net Worth
Market Cap & Net Worth: SIMCERE PHARMAC. GRP LTD (S2P)
SIMCERE PHARMAC. GRP LTD (F:S2P) has a market capitalization of $3.17 Billion (€2.72 Billion) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #4770 globally and #800 in its home market, demonstrating a -2.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SIMCERE PHARMAC. GRP LTD's stock price €1.23 by its total outstanding shares 2580646618 (2.58 Billion). Also see S2P current and non-current assets for a full breakdown of the balance sheet.
SIMCERE PHARMAC. GRP LTD Market Cap History: 2020 to 2026
SIMCERE PHARMAC. GRP LTD's market capitalization history from 2020 to 2026. Data shows growth from $1.24 Billion to $3.71 Billion (16.16% CAGR). Also see SIMCERE PHARMAC. GRP LTD (S2P) cash flow conversion for how efficiently the company converts equity into cash flow.
SIMCERE PHARMAC. GRP LTD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SIMCERE PHARMAC. GRP LTD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check SIMCERE PHARMAC. GRP LTD (S2P) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.50x
SIMCERE PHARMAC. GRP LTD's market cap is 0.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.85x
SIMCERE PHARMAC. GRP LTD's market cap is 2.85 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.49 Billion | $5.00 Billion | $1.51 Billion | 0.30x | 0.99x |
| 2022 | $2.49 Billion | $6.32 Billion | $930.87 Million | 0.39x | 2.67x |
| 2023 | $1.72 Billion | $6.61 Billion | $714.76 Million | 0.26x | 2.40x |
| 2024 | $2.49 Billion | $6.64 Billion | $722.00 Million | 0.38x | 3.45x |
| 2025 | $3.83 Billion | $7.73 Billion | $1.34 Billion | 0.50x | 2.85x |
Competitor Companies of S2P by Market Capitalization
Companies near SIMCERE PHARMAC. GRP LTD in the global market cap rankings as of September 19, 2026. Review SIMCERE PHARMAC. GRP LTD (S2P) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to SIMCERE PHARMAC. GRP LTD by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
SIMCERE PHARMAC. GRP LTD Historical Marketcap From 2020 to 2026
Between 2020 and today, SIMCERE PHARMAC. GRP LTD's market cap moved from $1.24 Billion to $ 3.71 Billion, with a yearly change of 16.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.71 Billion | -3.15% |
| 2025 | €3.83 Billion | +53.94% |
| 2024 | €2.49 Billion | +45.04% |
| 2023 | €1.72 Billion | -31.01% |
| 2022 | €2.49 Billion | +67.04% |
| 2021 | €1.49 Billion | +20.10% |
| 2020 | €1.24 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of SIMCERE PHARMAC. GRP LTD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.17 Billion USD |
| MoneyControl | $3.17 Billion USD |
| MarketWatch | $3.17 Billion USD |
| marketcap.company | $3.17 Billion USD |
| Reuters | $3.17 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its princi… Read more